Sulfasalazine and 5-ASA compounds

New aminosalicylate formulations have recently been introduced for the treatment of inflammatory bowel disease. Trials in the past decade have convincingly demonstrated their effectiveness in mildly to moderately active ulcerative colitis and in relapse prevention. The rate of side effects was significantly lower with the new aminosalicylates than with conventional sulfasalazine treatment. The therapeutic effects of the new aminosalicylates in Crohn's disease have been less pronounced, and their role in this disease requires further trials.